ND-009

N/A

Report date: 2022/01/17 12:14:22

Base Information

Drug NameND-009

Drug Alias Nameanti-TNF-alpha antibody fragment (inflammatory bowel disease), Numabanti-TNF-alpha antibody fragment (inflammatory bowel disease), Tillotts PharmaND-009

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody

Mechanisms of ActionTumor necrosis factor α inhibitors

TargetsTumor necrosis factor α

Therapy Area/IndicationsInflammation

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesNumab Therapeutics Ag Tillotts Pharma Ag

China Registration ClassN/A

Develop Information

Active CompaniesNumab Therapeutics Ag Tillotts Pharma

Inactive CompaniesN/A

Active IndicationsInflammation

Inactive IndicationsN/A

Other Information

ATC CodeN/A